TY - JOUR
T1 - Biomarkers in cardiovascular disease
T2 - Integrating pathophysiology into clinical practice
AU - Parikh, Shailja V.
AU - de Lemos, James A
PY - 2006/10
Y1 - 2006/10
N2 - Biomarkers play an important role in the diagnosis, prognostic assessment, and management of patients with suspected acute coronary syndromes (ACS). Specific biomarkers identify different components of the pathophysiology of ACS: troponins are prototype markers of myocyte necrosis, natriuretic peptides reflect neurohormonal activation and hemodynamic stress, soluble CD40 ligand is an indicator of platelet activation, and C-reactive protein, myeloperoxidase, and monocyte chemoattractant protein-1 reflect various inflammatory processes. When combined, multiple biomarkers reflecting different pathophysiologic processes appear to enhance risk stratification, as compared with using individual markers alone. Advances in proteomic technology promise to identify additional novel biomarkers that facilitate diagnosis, risk stratification, and selection of therapies in ACS. In the future, it is hoped that multiple biomarker panels will form the basis of an individualized approach to the treatment of ACS, in which therapy is tailored to individual biomarker profiles.
AB - Biomarkers play an important role in the diagnosis, prognostic assessment, and management of patients with suspected acute coronary syndromes (ACS). Specific biomarkers identify different components of the pathophysiology of ACS: troponins are prototype markers of myocyte necrosis, natriuretic peptides reflect neurohormonal activation and hemodynamic stress, soluble CD40 ligand is an indicator of platelet activation, and C-reactive protein, myeloperoxidase, and monocyte chemoattractant protein-1 reflect various inflammatory processes. When combined, multiple biomarkers reflecting different pathophysiologic processes appear to enhance risk stratification, as compared with using individual markers alone. Advances in proteomic technology promise to identify additional novel biomarkers that facilitate diagnosis, risk stratification, and selection of therapies in ACS. In the future, it is hoped that multiple biomarker panels will form the basis of an individualized approach to the treatment of ACS, in which therapy is tailored to individual biomarker profiles.
UR - http://www.scopus.com/inward/record.url?scp=33749862787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749862787&partnerID=8YFLogxK
U2 - 10.1097/00000441-200610000-00006
DO - 10.1097/00000441-200610000-00006
M3 - Article
C2 - 17031244
AN - SCOPUS:33749862787
SN - 0002-9629
VL - 332
SP - 186
EP - 197
JO - The American journal of the medical sciences
JF - The American journal of the medical sciences
IS - 4
ER -